Ultime notizie per Canopy Gwth (NASDAQ:CGC) Azioni

Canopy Gwth

Canopy Growth

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include skincare products under Martha Stewart CBD and Storz & Bickel vaporizers. Canopy growth merged its US assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.

Canopy Growth Corporation - Common Shares

Canopy Growth Corp

Capital Group Core Bond ETF

CENTRAL GLASS CO LTD ORD by Central Glass Co., Ltd.

Central Glass Co Ltd

COMMERCE GROUP CORP by Commerce Group Corp.

Commerce Group Corp

Capital Group Core Plus Income ETF

Capital Group Conservative Equity ETF

Cannabis

Politics

Markets

General

AAWH

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

AUSAF

AVTBF

AYRWF

BBRRF

BHHKF

BLOZF

BMMJ

CANN

CBDY

CBMJ

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CHOOF

CLSH

CLVR

CNBS

CNBX

CNGGF

CNPOF

CNTMF

CNVCF

CPHRF

CRLBF

CRON

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVHIF

CVSI

CWBHF

CANNIBIS GROWTH OPTY CORP by Cannabis Growth Opportunity Corp.

CWWBF

CXXIF

ELLXF

EMOR

ETST

EVIO

FFLWF

FFNTF

FUTURE FARM TECHNOLOGIES by Future Farm Technologies Inc.

FFRMF

FLGC

FLOOF

FLWPF

FINCANNA CAPITAL CORP by Fincanna Capital Corp.

FNNZF

FUAPF

GABRIELLAS KITCHEN INC by Gabriella's Kitchen Inc.

GABLF

GBHPF

GENE

GHBWF

GLASF

GNLN

GRAMF

GRNH

GRWG

GREEN SPIRIT INDUSTRIES by Green Spirit Industries Inc.

GSRX

GTBIF

HBOSF

HEMP

HERTF

HHPHF

HMLSF

IIPR

INCR

INLB

ISODIOL INTERNATIONAL ORD by Isodiol International Inc.

ISOLF

ITHUF

IVITF

JWCAF

KALY

KAYS

KHIRON LIFE SCIENCES CORP by Khiron Life Sciences Corp.

KHRNF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LFCOF

LFLY

LIFD

LMLLF

LNLHF

LOVFF

LRSNF

LVRLF

LXLLF

MAPS

MGCLF

MGWFF

MJNE

MJUS

MMNFF

MPXOF

MRMD

NDVAF

NOBDF

NWVCF

OILFF

PHOT

PKPH

AP Reports Florida Voters Reject Cannabis Legalization; Amendment 3 Did Not Secure 60% Of Vote

U.S. stocks were lower, with the Dow Jones index falling around 300 points on Monday.
Shares of Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) rose sharply during Monday's session after the company reported better-than-expected third-quarter financial results.
Integra Lifesciences reported quarterly earnings of 41 cents per share which beat the analyst consensus estimate of 39 cents per share. The company reported quarterly sales of $380.83 million which beat the analyst consensus estimate of $375.78 million.
Integra LifeSciences shares jumped 24.4% to $23.96 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares jumped 43% to $66.22 after the company entered a securities purchase agreement for a PIPE investment, expected to bring in gross proceeds of $200 million.</li>
<li>Air Transport Services Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) gained 26.4% to $22.01 after the company announced it will be acquired by Stonepeak for approximately $3.1 billion, with shareholders receiving $22.50 per share in cash.</li>
<li>Xiao-I Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) rose 24.2% to $7.14. Xiao-I entered into private placement &amp; securities purchase agreement to issue, sell convertible promissory note for $2.1 million.</li>
<li>Disc Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) gained 22.9% to $57.93 after the company announced the end of its Phase 2 Bitopertin In Erythropoietic Protoporphyria meeting with the FDA. The company is aligned with the FDA across all proposed study parameters and has a clear development path to registration.</li>
<li>Globalstar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NASDAQ">GSAT</a>) gained 21.8% to $1.6800.</li>
<li>Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) rose 16% to $5.64.</li>
<li>The Chemours Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>) gained 14.6% to $20.42 after the company reported better-than-expected quarterly financial results.</li>
<li>Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) rose 13.5% to $7.61.</li>
<li>Evotec SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NYSE">EVO</a>) jumped 13.1% to $4.3850.</li>
<li>LexinFintech Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LX#NYSE">LX</a>) gained 12.8% to $3.6100.</li>
<li>Freshpet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) gained 10.9% to $148.32 after the company reported better-than-expected quarterly financial results and raised its full-year adjusted EBITDA outlook.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) rose 9.4% to $10.88.</li>
<li>Yum China Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) surged 8.1% to $48.73 after the company reported better-than-expected quarterly EPS and revenues.</li>
<li>Nextracker Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) gained 8% to $42.75.</li>
<li>Peloton Interactive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) rose 7.5% to $7.80.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) gained 7.5% to $1.2250.</li>
<li>Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) gained 7.3% to $29.13 after it was announced that the company will join the S&amp;P MidCap 400 prior to the opening of trading on Wednesday, Nov. 6.</li>
<li>Bath &amp; Body Works, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NASDAQ">BBWI</a>) rose 7.2% to $30.99.</li>
<li>Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) gained 5.6% to $ 38.29</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41713625/this-roblox-analyst-turns-bullish-here-are-top-5-upgrades-for-monday">This Roblox Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday</a></li>
</ul>

News

Intraday Update

Movers

AIXI

ARRY

ATSG

BBWI

CHWY

FRPT

GSAT

IART

IRON

NGNE

PSNY

PTON

YUMC

Integra LifeSciences Posts Upbeat Results, Joins Air Transport Services, Freshpet, Yum China And Other Big Stocks Moving Higher On Monday

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/AUSAF">Australis Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AUSAF#OTC">AUSAF</a>) shares closed up 100.00% at $0.0002</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed up 65.54% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed up 60.00% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 54.44% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 50.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNPOF">RIV Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) shares closed up 10.29% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed up 10.20% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CARA">Cara Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed up 9.40% at $0.29</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed up 5.22% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 4.89% at $2.70</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 3.05% at $0.05</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CNGGF">Cann Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNGGF#OTC">CNGGF</a>) shares closed down 84.57% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed down 23.95% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 18.75% at $3.04</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 11.44% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 10.23% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 7.51% at $1.81</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 6.10% at $4.95</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed down 4.07% at $0.13</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed down 4.05% at $2.14</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 4.03% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/CRON">Cronos Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) shares closed down 3.65% at $2.11</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CARA

RMHB

SNDL

SOLCF

UGRO

XXII

Cannabis Stock Gainers And Losers From November 1, 2024

As the cannabis industry maneuvers through financial complexities and regulatory uncertainties, recent updates from Tilray Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), High Tide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) and Glass House Brands Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GLASF#OTC">GLASF</a>) offer a clear glimpse into the fiscal health and strategic pivots of these market leaders.
Each company's Q3 and Q1 financials, as examined by Elevetix, a company providing research and consulting for companies and investors in cannabis and AgriTech sectors, reveal varied approaches to market share, cost control and potential growth in Canada, the U.S. and Europe.
<h3 class="wp-block-heading">HITI's Market Expansion Across Canada And Beyond</h3>
High Tide&#8217;s Q3 report radiates positivity, <a href="https://www.benzinga.com/markets/cannabis/24/09/40920148/exclusive-high-tide-ceo-highlights-major-drivers-behind-record-earnings-market-share-growth">with the company marking a notable expansion across Canada</a>, Germany and the U.S. Its revenue climbed to CAD 131.7 million ($94.4 million), representing a 6% increase year-over-year, complemented by a strong 12% market share in the operational provinces. Noteworthy is its aggressive pricing strategy aimed at ousting competitors, which seems to be paying off as evidenced by its growing market share and stable gross margins at 27%. 
Moreover, Elevetix notes the firm also boasts a swelling loyalty program, suggesting robust consumer retention and engagement.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Another milestone for <a href="https://twitter.com/HighTide_HITI?ref_src=twsrc%5Etfw">@HighTide_HITI</a>. Very pleased to announce that we now have our 1st equity research analyst based in Europe, as Nik Faes of ELEVETIX issued a report today. We now have 7 analysts providing research coverage on our shares &#8211; momentum continues to build! <a href="https://twitter.com/search?q=%24HITI&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$HITI</a>
&mdash; Raj Grover &#x1f1e8;&#x1f1e6; (@RajGrover_HITI) <a href="https://twitter.com/RajGrover_HITI/status/1852038663879700620?ref_src=twsrc%5Etfw">October 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">TLRY Operational Losses Reflect Cost Struggles</h3>
In contrast, Tilray&#8217;s <a href="https://www.benzinga.com/markets/cannabis/24/10/41273594/tilray-reports-200m-q1-net-revenue-up-13-yoy-as-net-loss-improves">Q1 revelations detail a struggle to maintain momentum</a>. Despite a 13% increase in net revenue, reaching $200 million, largely fueled by its alcoholic segment, its cannabis business continues to underperform with a 13% decline. The operational loss widened to $37 million, highlighting <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41613366/beyond-beer-tilrays-1-67-billion-market-play-is-this-cannabis-giant-still-a-smart-b">ongoing challenges in market positioning and cost management</a>.
According to the Elevetix reports, Tilray's strategic maneuvers, including potential acquisitions of Aurora Cannabis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) and Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>)&#8217;s non-U.S. operations, suggest a pivot towards strengthening its medical cannabis footprint in international markets.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41478283/female-cannabis-consumers-outspend-men-how-tilray-and-high-tide-are-responding">Female Cannabis Consumers Outspend Men: How Tilray And High Tide Are Responding</a>
<h3 class="wp-block-heading">GLASF Targets Cost Leadership</h3>
On the other hand, Glass House Brands underscores its ambition to dominate through cost leadership in cultivation. Reporting the lowest production cost among North American growers, the company aims to slash it further from $130 to $100 per pound. Its expansion strategy is tightly coupled with regulatory shifts, particularly the federal rescheduling of cannabis, which could boost its operations nationally. 
Notably, management aims to manage dilution through careful equity issuance and additional capital raises for expansion phases.
<h3 class="wp-block-heading">Election Uncertainty Impacts Cannabis Stocks</h3>
Elevetix&#8217;s latest investor briefings spotlight the <a href="http://benzinga.com/cannabis">cannabis sector's</a> resilience amid market pressures and election uncertainties. <a href="https://www.benzinga.com/markets/cannabis/24/10/41662424/cannabis-stocks-sink-amid-broader-market-decline-and-election-jitters">With cannabis stocks reflecting the broader economic downturn</a>, these insights into companies like Tilray, High Tide and Glass House Brands emphasize strategic adaptability in a volatile landscape.&nbsp;
As policy and economic shifts unfold, these companies' distinct approaches may offer investors crucial perspectives on industry stability and growth potential.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40465710/why-are-so-many-california-cannabis-companies-switching-to-hemp-products">Why Are So Many California Cannabis Companies Switching To Hemp Products?</a></li>
</ul>

HITI

TLRY

Tilray, High Tide, Glass House: How Top Cannabis Companies Deal With Financial Pressures

Cannabis Stock Gainers And Losers From October 31, 2024

Cannabis stocks are experiencing notable declines this Thursday, aligning with a general downturn across major economic indices. At the time of publication of this article, the S&amp;P 500 index was trading down by 1.62%, the Nasdaq 100 by 2.44%, and the Dow Jones Industrial Average (DJIA) showed a similar downward trend earlier in the day, only partially recovering.
This widespread decline points to a broader economic shift, with investors adopting a more cautious approach amid market volatility. 
The performance of these major indices often reflects investor sentiment across sectors, and the impact on cannabis stocks highlights their sensitivity to these broader economic movements.
<h3 class="wp-block-heading">Cannabis Stocks Hit Hard</h3>
Several prominent cannabis stocks saw significant drops today. Tilray Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) fell by 2.8%, Aurora Cannabis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) dropped by 4.14% and Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) saw a 6.67% decline. Other companies, like SNDL Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) and Cronos Group Inc. (NASDAD: CRON), also recorded losses. The downward trend isn't limited to individual companies; cannabis ETFs, such as the AdvisorShares Pure US Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>) and Amplify Alternative Harvest ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MJ#NYSE">MJ</a>), experienced losses as well. This widespread impact underscores the challenges cannabis stocks face in a volatile market.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="788" height="990" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31142536/Captura-de-pantalla-2024-10-31-a-las-15.25.12.png" alt="" class="wp-image-624602" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31142536/Captura-de-pantalla-2024-10-31-a-las-15.25.12.png 788w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31142536/Captura-de-pantalla-2024-10-31-a-las-15.25.12-239x300.png 239w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31142536/Captura-de-pantalla-2024-10-31-a-las-15.25.12-768x965.png 768w" sizes="(max-width: 788px) 100vw, 788px" /></figure>
Cannabis Stocks Watchlist In <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Movements recorder prior to the writing of this article.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41629360/criminal-organizations-lose-30m-annually-as-uruguays-legal-cannabis-expands-but-some-say-the-gov">Criminal Organizations Lose $30M Annually As Uruguay&#8217;s Legal Cannabis Expands, But Some Say The Government Is Now The Criminal</a>
<h3 class="wp-block-heading">Election Uncertainty Adds Pressure</h3>
Political factors may also be contributing to the <a href="https://www.benzinga.com/markets/cannabis/24/10/41656834/trump-harris-and-cannabis-stocks-are-election-results-already-priced-in">pressure on cannabis stocks</a>. 
With the upcoming U.S. elections, rising support for Donald Trump could signal potential GOP control of Congress. Historically, a Republican-led Congress has been less supportive of cannabis reform, raising concerns about policy stagnation for the industry. Investors might be factoring in this possibility, creating additional headwinds for cannabis-related equities in an already challenging market environment.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/10/41656834/trump-harris-and-cannabis-stocks-are-election-results-already-priced-in">Trump, Harris And Cannabis Stocks: Are Election Results Already Priced In?</a></li>
</ul>
COVER: AI-generated image

MSOS

Cannabis Stocks Sink Amid Broader Market Decline And Election Jitters

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/AUSAF">Australis Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AUSAF#OTC">AUSAF</a>) shares closed up 100.00% at $0.0002</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed up 65.54% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed up 60.00% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 54.44% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 50.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNPOF">RIV Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) shares closed up 10.29% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed up 10.20% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CARA">Cara Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed up 9.40% at $0.29</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed up 5.22% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 3.51% at $2.70</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 3.05% at $0.05</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CNGGF">Cann Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNGGF#OTC">CNGGF</a>) shares closed down 84.57% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed down 23.95% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 18.75% at $3.04</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 11.44% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 10.23% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 7.51% at $1.81</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 6.10% at $4.95</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed down 4.07% at $0.13</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed down 4.05% at $2.14</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 4.03% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/CRON">Cronos Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) shares closed down 3.65% at $2.11</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis Stock Gainers And Losers From October 30, 2024

Microsoft shares are trading higher after the company reported better-than-expected Q1 2025 GAAP EPS and sales.

Canada's cannabis market is seeing a chilling stagnation, with 2024 showing nearly zero growth in consumer sales—a stark contrast to the double-digit gains of previous years.
Amid this slowdown, certain products capture consumer interest, even as prices stabilize and competition intensifies. In his latest analysis, senior analyst Pablo Zuanic of <a href="https://zuanicgroup.com/">Zuanic &amp; Associates</a> explores what's still selling in a market haunted by stagnation and shifting dynamics.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Flower Segment: Stabilized Prices And Market Fragmentation</h3>
The flower segment remains essential to <a href="https://www.benzinga.com/topic/canada-cannabis">Canada's cannabis sales</a>, though dynamics among top players are shifting. Village Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) leads with a 15% share, though down from 17.4% in Q2 2024, followed by Tilray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) at 12.8%, Organigram (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) and Cronos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) at 10.8% and 6.1%, respectively.
Mid-tier players include Auxly (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>), Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>), and Cannara Biotech (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LOVFF#OTC">LOVFF</a>), each with 2-5% shares.
Average flower prices stabilized at CAD 5 per gram ($3.70), up slightly from CAD 4.80 last year, though individual prices vary slightly by producer.
<h3 class="wp-block-heading">Pre-Rolls Gain Ground, With Decibel Leading In Infused Joints</h3>
Pre-rolls have reached parity with flower sales, each making up 35% of the market, reflecting <a href="https://www.benzinga.com/topic/cannabis-marketing">a shift in consumer preferences</a>. Decibel (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DBCCF#OTC">DBCCF</a>) holds a 10.8% share of this segment, followed by Tilray at 8.5%, Organigram at 6.4%, and Village Farms at 5.4%.
Subcategory breakdowns show joints leading with 55% of sales, while <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36268367/u-s-cannabis-market-premium-products">infused joints </a>make up 27%. Decibel, once a leader in infused joints, saw its dominance decrease from 55% in Q3 2023 to 38% in Q3 2024.
Mid-range pre-roll players include BZAM with 4.2%, Weed Me (private) with 3.9%, and Auxly with 3.3%.
Read Next:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41561831/m-a-frenzy-and-deflation-post-election-which-companies-are-ready-to-win-big-in-flor"> M&amp;A Frenzy And Deflation Post-Election: Which Companies Are Ready To Win Big In Florida&#8217;s Cannabis Market</a>
<h3 class="wp-block-heading">Vape Segment: Motif Labs Dominates 510 Cartridges</h3>
Vapes now comprise 16% of the <a href="https://www.benzinga.com/topic/canada-cannabis">Canadian cannabis market</a>, led by Motif Labs with a 20.6% share, followed by Auxly at 12.9%, Decibel at 9.7%, and Cronos at 7.3%. The 510 cartridges, particularly in 1ml and 1.2ml formats, dominate vape sales with 74% of the market, underscoring their popularity.
Disposables and live resin cartridges have smaller shares, with closed-loop systems representing 2% of sales. Tilray and Cannara also hold smaller but significant shares in this segment, at 4.9% and 3.4%, respectively.
<h3 class="wp-block-heading">International Ventures: The Next Growth Frontier?</h3>
While the domestic market stagnates, Zuanic notes a shift in investor focus toward <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39609582/europe-is-turning-cash-flow-positive-well-see-what-happens-in-the-u-s-largest-canna">companies with international strategies</a>, especially given potential U.S. regulatory reforms.
"Canadian LPs are positioning for U.S. entry and<a href="https://www.benzinga.com/markets/cannabis/24/06/39442869/2-9b-european-cannabis-market-a-strategic-blueprint-for-cross-border-transportation-logistics"> European expansion</a>, focusing less on local sales growth," he explains, suggesting that global ventures could provide critical revenue streams as companies seek growth beyond Canada's limited market.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/10/41502695/exclusive-tilray-ceo-irwin-simon-on-why-us-cannabis-rescheduling-wont-change-a-billion-dollar-pl">EXCLUSIVE: Tilray CEO Irwin Simon On Why US Cannabis Rescheduling Won&#8217;t Change A Billion-Dollar Play</a>

Analyst Color

Market Summary

Guidance

Retail Sales

Management

Analyst Ratings

DBCCF

Canada's Cannabis Market Goes Cold, Pot Prices Hit Bottom: Why Top Producers Are Losing Ground

Cannabis stocks are showing signs of recovery, with several major players gaining momentum on Friday.
NASDAQ-listed Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>),&nbsp;Aurora Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>),&nbsp;SNDL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) and&nbsp;OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>), among others, are all seeing upward trends in their stock prices. While each stock shows promise, their outlooks differ based on key technical factors. Let's break down what's happening with these stocks and what to watch out for next.
<h3 class="wp-block-heading">Canopy Growth (CGC)</h3>
Canopy Growth is currently trading at&nbsp;$5.39, up&nbsp;9.67%&nbsp;for the day. The stock has moved above its&nbsp;9-day moving average&nbsp;of&nbsp;$4.64, a sign of short-term strength. Canopy's&nbsp;MACD&nbsp;indicator is showing strong bullish momentum, suggesting that buying interest is increasing. However, the stock faces a critical resistance level at&nbsp;$6.00.
If Canopy can break through the&nbsp;$6.00&nbsp;level, it could continue to rise toward&nbsp;$7.00&nbsp;or more. But if it struggles to break this barrier, it might fall back to the&nbsp;$4.64&nbsp;support level, where it has bounced from recently.
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="656" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130249/canopy-1-1024x656.png" alt="" class="wp-image-614986" style="width:546px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130249/canopy-1-1024x656.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130249/canopy-1-300x192.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130249/canopy-1-768x492.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130249/canopy-1-1536x984.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130249/canopy-1.png 1685w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
<h3 class="wp-block-heading">Aurora Cannabis (ACB)</h3>
Aurora Cannabis is up&nbsp;6.67%, trading at&nbsp;$6.05. Like Canopy, it is trading above its&nbsp;9-day moving average&nbsp;of&nbsp;$5.71, signaling bullish momentum. The&nbsp;MACD&nbsp;indicator is also positive, though Aurora's recovery has been more gradual than Canopy's.
Aurora's next resistance is at&nbsp;$6.50. A breakout above this level could see the stock head toward&nbsp;$7.00, but if the stock fails to break through, it could pull back to its&nbsp;$5.71&nbsp;support level.
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="665" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130300/aurora-1-1024x665.png" alt="" class="wp-image-614987" style="width:549px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130300/aurora-1-1024x665.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130300/aurora-1-300x195.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130300/aurora-1-768x498.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130300/aurora-1-1536x997.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130300/aurora-1.png 1664w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/09/41053445/cannabis-companies-delisted-from-major-stock-exchanges-in-2024-what-went-wrong"> Cannabis Companies Delisted From Major Stock Exchanges In 2024: What Went Wrong?</a>
<h3 class="wp-block-heading">SNDL (Sundial Growers)</h3>
SNDL is trading at&nbsp;$2.25, up&nbsp;6.40%, and has crossed above its&nbsp;9-day moving average&nbsp;of&nbsp;$2.07. The&nbsp;MACD&nbsp;is showing increasing buying pressure, but SNDL is known for its volatility. The stock faces resistance at&nbsp;$2.27, a level it has struggled with in the past.
If SNDL can break through&nbsp;$2.27, it could reach&nbsp;$2.50, but if it fails, a pullback to&nbsp;$2.07&nbsp;is possible.
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="664" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130236/sndl-1024x664.png" alt="" class="wp-image-614984" style="width:556px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130236/sndl-1024x664.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130236/sndl-300x194.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130236/sndl-768x498.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130236/sndl-1536x996.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130236/sndl.png 1666w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
<h3 class="wp-block-heading">OrganiGram Holdings (OGI)</h3>
OrganiGram is trading at&nbsp;$1.90, up&nbsp;6.15%. It's above its&nbsp;9-day moving average&nbsp;of&nbsp;$1.79, and the&nbsp;MACD&nbsp;is showing a slight bullish signal. OrganiGram faces a key resistance level at&nbsp;$2.00. If it breaks through this, it could see further gains toward&nbsp;$2.20. But if the stock fails to pass&nbsp;$2.00, it may consolidate around&nbsp;$1.79.
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="686" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130349/OGI-1024x686.png" alt="" class="wp-image-614993" style="width:565px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130349/OGI-1024x686.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130349/OGI-300x201.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130349/OGI-768x515.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130349/OGI-1536x1029.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25130349/OGI.png 1612w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
All four cannabis stocks are showing signs of recovery, with positive momentum and support from their moving averages. <a href="https://www.benzinga.com/markets/cannabis/24/10/41332773/flora-growth-teams-up-with-cannabis-giant-canopy-to-enter-94m-australian-medical-marijuana-marke">Canopy Growth</a> and <a href="https://www.benzinga.com/markets/cannabis/24/09/40970562/nasdaq-listed-aurora-cannabis-breaks-up-with-uruguay-its-not-you-its-the-market">Aurora</a> have more stable trajectories, while <a href="https://www.benzinga.com/markets/cannabis/24/10/41433854/sndl-completes-37m-nova-cannabis-acquisition-strengthening-canadian-market-position">SNDL</a> and <a href="https://www.benzinga.com/markets/cannabis/24/06/39484091/organigram-supports-cannabis-in-germany-with-15m-initial-investment-in-this-berlin-marijuana-co">OrganiGram</a> have greater potential for both gains and volatility.
Investors should keep an eye on these resistance levels.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/10/41489067/advisorshares-msos-climbs-8-as-cannabis-rescheduling-sparks-investor-interest">AdvisorShares MSOS Climbs 8% As Cannabis Rescheduling Sparks Investor Interest</a></li>
</ul>
Cover: AI generated image
Disclosure: this article is not intended to provide financial advice. Consult a professional before making investment decisions.

Market-Moving Exclusives

Cannabis Stocks Rally: Canopy, Aurora, SNDL, OrganiGram And Others See Gains

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 61.29% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 38.16% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 20.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 17.86% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 14.29% at $4.98</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed up 13.24% at $3.55</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed up 12.57% at $0.12</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 12.38% at $2.25</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed up 9.80% at $6.10</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed up 8.97% at $1.70</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 7.97% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed up 7.97% at $11.11</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed up 7.61% at $1.71</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed up 7.47% at $13.30</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 7.39% at $0.25</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed up 6.47% at $2.15</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 5.42% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CRON">Cronos Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) shares closed up 4.23% at $2.29</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 3.43% at $0.17</li>
<li><a href="https://www.benzinga.com/quote/CARA">Cara Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed up 3.16% at $0.27</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/GEATF">Radiko Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GEATF#OTC">GEATF</a>) shares closed down 90.00% at $1e-06</li>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed down 20.11% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 15.22% at $1.62</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed down 12.52% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 9.89% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed down 7.69% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 7.22% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 6.14% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 5.58% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed down 3.69% at $0.52</li>
<li><a href="https://www.benzinga.com/quote/SMG">Scotts Miracle Gro</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) shares closed down 3.44% at $86.75</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GEATF

RSSFF

TCNNF

ZDPY

Marijuana Stock Movers For October 22, 2024

Cannabis Stock Movers For October 22, 2024

<a href="https://www.marijuanamoment.net/legislative-committee-in-ireland-calls-for-marijuana-legalization-and-decriminalization-of-all-illicit-drugs/">https://www.marijuanamoment.net/legislative-committee-in-ireland-calls-for-marijuana-legalization-and-decriminalization-of-all-illicit-drugs/</a>
After lawmakers in Ireland <a href="https://www.marijuanamoment.net/irelands-government-proposes-nine-month-delay-on-marijuana-legalization-bill-vote-calling-for-special-committee/">delayed a vote on marijuana legalization earlier this year</a> in favor of further studying the issue, a special legislative committee on drug policy has published an interim report with nearly 60 recommendations, calling for changes such as the limited legalization of marijuana and the decriminalization of personal use and possession of all illegal drugs.
The new report, released on Tuesday, is the product of the Oireachtas Joint Committee on Drugs Use, which was formed to consider cannabis legalization and other drug policy issues following the release of a <a href="https://www.marijuanamoment.net/as-irish-lawmakers-prepare-to-debate-marijuana-bill-prime-minister-pledges-to-examine-drug-decriminalization-as-recommended-by-citizen-commission/">citizen commission report in January that recommended broadly decriminalizing drugs</a>&nbsp;and implementing harm reduction programs.
Gino Kenny, the chair of the committee and a member of Ireland's lower house of parliament, <a href="https://www.irishexaminer.com/news/arid-41501180.html">told</a> Irish Examiner that the proposal could allow cannabis clubs where members can purchase small amounts of marijuana grown on a nonprofit basis, which <a href="https://www.marijuanamoment.net/german-officials-approve-countrys-first-marijuana-social-club-since-legalization-took-effect/">some other European countries permit</a>, but may also allow for broader commercial legalization.
"It's important that this is implemented," Kenny told the paper, emphasizing his perspective that the government should adopt a "health-led approach" to drug use.
&nbsp;
Indeed, many of the 59 recommendations from the special committee focus on shifting the paradigm around drug control from one of punishment and stigma to one of health and harm reduction. That's the core of the first six recommendations laid out in the committee's description of its interim report, which includes findings that "the stigmatisation of drug use and the shaming of drug users are a source of significant harm" and that "the goal of drug policy should be to reduce harm and eliminate stigma."
To that end, it says, "the decriminalization of possession for personal use should apply equally to all illicit drugs." And while "people should be offered all supports and health resources that are required," it adds, "no person should be criminalised for not availing of a supportive intervention."
When it comes to marijuana, the committee is calling on health and justice officials to "undertake a body of research into how a regulated drug market could operate in Ireland beginning with cannabis, and how Ireland can incorporate and implement the learnings of other jurisdictions that have taken positive steps in this regard."
The report specifies that the country should consider reforms "with particular reference to Spain, Malta, and Germany in the development of an Irish not for profit regulated cannabis market."
The body is also calling for expansion of the country's medical marijuana program "to ensure that more people affected by chronic illness can access cannabis in circumstances where other treatments have failed to relieve symptoms."
The recommendations also advise that local authorities and An Garda Síochána—the country's national police force—"are supported and empowered in strongly discouraging and reducing consumption in public areas." The committee suggested that "specific trauma and harm reduction training be provided to An Garda Síochána and local authorities, to inform their work with individuals and communities affected by drug misuse and addiction."
Kenny, the committee chair, noted that the body's <a href="https://www.oireachtas.ie/en/press-centre/press-releases/20241022-joint-committee-on-drugs-use-publishes-interim-report-with-59-recommendations/">recommendations</a> are "very clear that the supply and sale of drugs should remain illegal" and acknowledged that drugs can cause "huge damage" to individuals, families and communities, especially among already disadvantaged groups. But he said the committee was in broad agreement that criminalizing substances is the wrong approach.
"There's still a lot to look at of course, but between the work done by the Committee and the Citizens' Assembly, it's clear that there is a consensus that criminalising and prosecuting the use of drugs for personal drug use is a waste of money and is very detrimental to anyone convicted," he said in a statement.
After months of study, he added, "there's no excuse for a new Government to say that issues around the decriminalisation of drugs for personal use haven't been discussed properly. Both the Citizens' Assembly and the Oireachtas Joint Committee on Drugs Use have looked at the issue in detail."
When the committee was first being formed, Ryan McHale, executive committee member of the Irish drug policy reform organization Crainn, told Marijuana Moment that he felt the extra step was a "delay tactic from the Irish Government," which he called "disappointing given the clear calls from the Citizens' Assembly and overwhelming public support for the measure."
"The government are aware of the overwhelming support which is why they didn't outright oppose the bill like they did in 2013, which was the last attempt to liberalize cannabis laws," McHale said. "While there appears to be a shift from government in terms of changing Ireland's drug laws, they have not yet committed to any substantial legal change."
"This delay will mean that hundreds of people will be criminalized for personal possession of cannabis while the Irish government ponder the political effectiveness of reform," he added. "We cannot wait anymore and the Citizens' Assembly have been clear in their calls for change to the harmful status quo."
TD Paul Murphy said the government's proposed delay is "simply an attempt to kick the can down the road."
"They talk about a health led approach to drugs," he said. "Now it's time to walk the walk."
The cannabis legalization bill from Kenny that prompted the committee's formation was first introduced in 2022.
Ireland's taoiseach—or prime minister—Leo Varadkar <a href="https://www.marijuanamoment.net/as-irish-lawmakers-prepare-to-debate-marijuana-bill-prime-minister-pledges-to-examine-drug-decriminalization-as-recommended-by-citizen-commission/">told lawmakers earlier this year that he agrees prohibition doesn't work</a>, as evidenced by prohibition periods in Ireland that created illicit markets with "impure" alcohol products.
"In my view, drug use and misuse by individuals should be seen primarily as a public health issue and not a criminal justice matter," Varadkar said. "I certainly think that shaming people and blaming people and criminalizing people isn't an effective policy."
The Citizens' Assembly on Drugs Use considered marijuana legalization as part of its work last year, but a <a href="https://www.marijuanamoment.net/irish-citizens-panel-votes-to-recommend-decriminalizing-drug-possession-but-marijuana-legalization-falls-one-vote-short/">recommendation to enact the reform came up short by one vote</a>.
A year ago, the citizens' group posted summaries of 36 policy recommendations online—the culmination of what the body's chair, Paul Reid, called "the most comprehensive, wide-ranging, and representative discussion on all aspects of drugs use and drugs policy that has ever taken place in Ireland."
The group's overarching message, Reid said in a statement at the time, was that lawmakers must "take a much more ambitious and progressive approach to dealing with drugs in Ireland."
"Ultimately, it will be up to the Oireachtas to implement what the Assembly has called for," he said, referring to Ireland's national parliament. "But if they do, this will not only change the national policy and approach, it will also change people's lives. For the better."

Global

AKAN

iShares MSCI Ireland Capped Investable Market Index Fund

EIRL

IMCC

"Legislative Committee In Ireland Calls For Marijuana Legalization And Decriminalization Of 'All Illicit Drugs'" - Marijuana Moment

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 22.74% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/MGWFF">Maple Leaf Green World</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGWFF#OTC">MGWFF</a>) shares closed up 14.11% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed up 11.48% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 9.03% at $4.50</li>
<li><a href="https://www.benzinga.com/quote/EAST">Eastside Distilling</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) shares closed up 6.49% at $0.63</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 6.36% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed up 6.33% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 4.37% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 4.22% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed up 4.14% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 3.02% at $4.44</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 28.57% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed down 26.92% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 15.15% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 7.45% at $2.38</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 7.37% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 6.54% at $0.22</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 6.49% at $1.64</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 5.29% at $0.16</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EAST

Marijuana Stock Movers For October 18, 2024

Cannabis giant Canopy Growth Corporation (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WEED#TSX">WEED</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) has made an early payment of $100 million on its senior secured loan at a discounted price of $97.5 million. This move reduces the company&#8217;s debt and saves around $14 million in annual interest costs, while highlighting its focus on financial discipline.
&#8220;This early prepayment reflects our ongoing commitment to reducing cash burn and strengthening our capital structure," stated Judy Hong, CFO of Canopy Growth. "Our proactive steps to reduce debt and extend maturity enhance our balance sheet flexibility to invest in growth areas and drive long-term value creation for our shareholders.&#8221;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41365990/cannabis-debt-looms-for-these-weed-giants-heres-how-some-tackled-their-financial-challenges">Cannabis Debt Looms For These Weed Giants: Here&#8217;s How Some Tackled Their Financial Challenges</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
As previously announced in August 2024, this prepayment was agreed to between the company and its senior lenders as part of a series of amendments to the term loan which, among other things, included an extension of the term loan&#8217;s maturity date to Dec. 18, 2026. Under the loan amendment, Canopy Growth has the option to make an additional prepayment equal to $100 million at a discounted price of $97.5 million by March 31, 2025. If payment of the second prepayment is made, the maturity date of the term loan will automatically further extend to September 18, 2027.
The company's move to improve its balance sheet, comes on the heels of Canopy Growth's <a href="https://www.benzinga.com/markets/cannabis/24/10/41251114/cannabis-giant-canopy-expands-us-presence-with-acquisition-of-top-edibles-brand-what-it-means-fo">acquisition of top edibles brand – Wana</a>, which generated roughly $150 million in retail sales across 19 states in 2023. The deal includes Wana Wellness, LLC, The CIMA Group, LLC, and Mountain High Products, LLC. The top edibles brand, Wana,
<h2 class="wp-block-heading">CGC Price Action</h2>
Canopy Growth shares traded 0.70% lower at $4.23 per share during Thursday's pre-market session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41332773/flora-growth-teams-up-with-cannabis-giant-canopy-to-enter-94m-australian-medical-marijuana-marke">Flora Growth Teams Up With Cannabis Giant Canopy To Enter $94M Australian Medical Marijuana Market</a></li>
</ul>
Photo: Courtesy of Branding Pot via Shutterstock

TSX:WEED

WEED

Canopy Growth Slashes Debt With $100M Loan Prepayment, Saves $14M In Interest

Canopy Growth Reports Early Prepayment Under Its Senior Secured Term Loan In An Aggregate Principal Amount Equal To $100M At Discounted Price Of $97.5M

Flora Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>) signed a distribution agreement with Canopy Growth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) for the distribution of Canopy&#8217;s Storz &amp; Bickel medical line of vaporizers in Australia. Flora's subsidiary Australian Vaporizers will be in charge of distribution.
&#8220;Canopy Growth is a market leader with a $400 million market capitalization. We are very much interested in partnering with Canopy Growth to bring their highly regarded Storz vaporizers to the Australian market,&#8221; stated Clifford Starke, chairman and chief executive officer. &#8220;With Australian Vaporizers at the forefront of this initiative, we are confident that our distribution of Canopy&#8217;s Storz products will further enhance the standard of care for medical cannabis patients in Australia.&#8221;
Australian Vaporizers will spearhead the distribution of Storz vaporizers to healthcare professionals and clinics across the country. This agreement will enable Flora to meet the growing demand for various medical cannabis consumption solutions and further advance the company's position in the burgeoning Australian medical marijuana industry. According to Grand View Research, the Australian medical cannabis market size was estimated at $94 million and is projected to grow at a CAGR of 33.6% from 2024 to 2030.
Canopy Growth&#8217;s Storz vaporizers are designed specifically to meet the needs of the medical cannabis community, focusing on patient safety and offering some of the most innovative products on the market. Each device is built with precision for optimal dosing and efficiency to ensure users receive a consistent and controlled experience.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40313088/the-whole-world-is-in-overdose-says-ceo-of-company-behind-cannabis-inhaler-that-enables-controll">&#8216;The Whole World Is In Overdose,&#8217; Says CEO Of Company Behind Cannabis Inhaler That Enables Controlled Dosing</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h2 class="wp-block-heading">Flora Growth's Recent Milestones</h2>
The news follows up on Flora Growth's recent moves across Europe, such as <a href="https://www.benzinga.com/markets/cannabis/24/09/41029375/flora-growth-scores-exclusive-distribution-deal-with-canapuff-for-vessel-brand-in-czech-republic">an exclusive distribution deal</a> with Canapuff, a Czech Republic-based provider of <a href="https://www.benzinga.com/cannabis" target="_blank" rel="noreferrer noopener">cannabinoid consumer products.</a> This partnership will introduce Flora's Vessel brand of cannabis accessories into the Czech market, one of Central Europe's most progressive.
The company also recently signed a supply agreement with Blossom Genetics to bring Colombian medical cannabis <a href="https://www.benzinga.com/topic/germany-cannabis" target="_blank" rel="noreferrer noopener">to the German market</a>.This collaboration will introduce two strains, Chemmy Jones and Northern Lights, to the European country. The move follows the company&#8217;s recent acquisition of <a href="https://www.benzinga.com/markets/cannabis/24/04/38297284/another-cannabis-pioneer-expands-in-germany-via-acquisition-as-experts-say-theres-no-stepping-ba" target="_blank" rel="noreferrer noopener">Germany-based TruHC Pharma GmbH</a> in response to the country's <a href="https://www.benzinga.com/markets/cannabis/24/04/38023610/heres-what-you-need-to-know-about-weed-legalization-in-germany-that-just-took-effect" target="_blank" rel="noreferrer noopener">recent cannabis reform.</a>
<h2 class="wp-block-heading">FLGC Price Action</h2>
Flora Growth shares closed Monday's market session 8.87% lower at $1.85 per share.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41251114/cannabis-giant-canopy-expands-us-presence-with-acquisition-of-top-edibles-brand-what-it-means-fo">Cannabis Giant Canopy Expands US Presence With Acquisition Of Top Edibles Brand: What It Means For Investors</a></li>
</ul>
Photo: Courtesy of SD_FlowerPower via Shutterstock

Flora Growth Teams Up With Cannabis Giant Canopy To Enter $94M Australian Medical Marijuana Market

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 80.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed up 29.34% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 24.65% at $0.27</li>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed up 17.79% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 16.19% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed up 14.73% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 11.36% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed up 10.67% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/GENE">Genetic Technologies</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENE#NASDAQ">GENE</a>) shares closed up 10.60% at $0.75</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed up 10.18% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 9.38% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 8.00% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 7.74% at $0.17</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 6.38% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 6.17% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed up 5.08% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed up 3.84% at $5.62</li>
<li><a href="https://www.benzinga.com/quote/CNPOF">RIV Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) shares closed up 3.81% at $0.14</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 3.47% at $4.19</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed up 3.03% at $0.05</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed down 24.38% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/MXC">Mexco Energy</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed down 9.93% at $12.20</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 9.72% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 8.77% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 6.94% at $2.02</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TGIFF

Bullish Monday For Marijuana Stocks - Body and Mind, Global Compliance Among Top Gainers

Bedrocan International, a producer of pharmaceutical-grade medicinal cannabis, is set to make a return to the Canadian market, reaffirming its long-held commitment to providing standardized medicinal cannabis for patients. The company recently acquired a facility in Scarborough, a strategic location that once served as its operational base in Canada, and has been granted a new cultivation license by Health Canada. Production is expected to begin in early 2025, marking Bedrocan's renewed presence in Canada after several years of absence.
"We have had a strictly pharmaceutical approach since our foundation in 2003. We use the knowledge we have acquired in more than twenty years of business to produce cannabis products that benefit patients exclusively," said Bedrocan's CEO Jaap Erkelens. Bedrocan's meticulous approach to production ensures consistent levels of THC and CBD in all of its products, offering patients a reliable, standardized therapeutic experience. This level of precision is critical for both patients and prescribing physicians who seek consistent outcomes from medical cannabis treatments.
In its return to the Canadian market, Bedrocan aims to introduce several of its standardized cannabis products, with the Bedrocan brand at the forefront. The company plans to distribute these products via a third party through the medical sales channel, providing registered patients with direct access to high-quality, medicinal cannabis.
The company's return follows a previous venture in Canada that ended with the termination of its partnership with Canopy Growth Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>). Despite this setback, Bedrocan remained steadfast in its desire to return to the Canadian market. "We are thrilled to be coming back to Canada," Erkelens said. "We look forward to serving patients in Canada and positively impacting the Canadian healthcare landscape."
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Cover image made with AI

European Cannabis Giant Bedrocan To Re-Enter Canadian Market With Pharmaceutical-Grade Products, New Facility

Comments

Canopy Gwth

Notizie

Ultime notizie per Canopy Gwth (NASDAQ:CGC) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO